COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.
Stay current on PCCA news and events, market trends, and all things compounding!
On February 20 at 3 p.m. CT, PCCA Clinical Compounding Pharmacist Sebastian Denison spoke about low-dose naltrexone (LDN) and its therapeutic benefits through compounding on the LDN Radio Show. He discussed the reasons why various strengths of LDN are needed based on patient response, as well as the importance of working with a qualified PCCA compounding pharmacist and using the highest quality chemicals from qualified wholesalers.
A service of the LDN Research Trust, whose primary aim is to initiate clinical trials of LDN for autoimmune diseases and cancers, the LDN Radio Show regularly features LDN prescribers, researchers and pharmacists from around the world. The founder of the LDN Research Trust, Linda Elsegood, is a featured speaker at PCCA’s 2019 Concierge Congress, April 25-27, in Chicago, Illinois.
Check out the interview here! Vimeo Vide: https://vimeo.com/311023812
MixCloud Audio: https://www.mixcloud.com/LDNRT/aaa/